Akari Therapeutics, Plc Research and Development Expense
Akari Therapeutics, Plc (AKTX) reported Research and Development Expense of $2.08 million for the 3-month period ending 2026-06-30, per its 10-Q filed 2026-08-13.
Financial Statements › Expense Statement › Operating Expenses
us-gaap:ResearchAndDevelopmentExpense · last filed 2026-08-13
- Akari Therapeutics, Plc research and development expense for the quarter ending 2026-06-30 was $2.08M, a 211.39% increase year-over-year.
- Akari Therapeutics, Plc research and development expense for the quarter ending 2026-03-31 was $1.46M, a 79.46% increase year-over-year.
- Akari Therapeutics, Plc research and development expense for the quarter ending 2025-12-31 was $1.09M, a 12.91% decline year-over-year.
- Akari Therapeutics, Plc research and development expense for the quarter ending 2025-09-30 was $249.00K, a 74.13% increase year-over-year.
- Akari Therapeutics, Plc research and development expense for fiscal 2025 was $2.81M, a 59.69% decline from fiscal 2024.
- Akari Therapeutics, Plc research and development expense for fiscal 2024 was $6.98M, a 28.13% increase from fiscal 2023.
- Akari Therapeutics, Plc research and development expense for fiscal 2023 was $5.45M.
- Akari Therapeutics, Plc research and development expense for fiscal 2013 was $1.28M, a 13.96% decline from fiscal 2012.
| Period end | Research and Development Expense 3 month | Research and Development Expense 3 month as first filed | Research and Development Expense 6 month | Research and Development Expense 6 month as first filed | Research and Development Expense 9 month | Research and Development Expense 12 month | Research and Development Expense 12 month as first filed | Research and Development Expense 99 month | Research and Development Expense 111 month |
|---|---|---|---|---|---|---|---|---|---|
| 2026-06-30 | $2.08M 10-Q · filed 2026-08-13 | $3.54M 10-Q · filed 2026-08-13 | $4.62M derived: sum of 3 quarters · filed 2026-08-13 | $4.87M derived: sum of 4 quarters · filed 2026-08-13 | |||||
| 2026-03-31 | $1.46M 10-Q · filed 2026-05-19 | $2.54M derived: sum of 2 quarters · filed 2026-05-19 | $2.79M derived: sum of 3 quarters · filed 2026-05-19 | $3.46M derived: sum of 4 quarters · filed 2026-08-13 | |||||
| 2025-12-31 | $1.09M derived: 10-K 12 month − 10-Q 9 month · filed 2026-03-30 | $1.33M derived: sum of 2 quarters · filed 2026-03-30 | $2.00M derived: sum of 3 quarters · filed 2026-08-13 | $2.81M 10-K · filed 2026-03-30 | |||||
| 2025-09-30 | $249.00K 10-Q · filed 2025-11-13 | $916.00K derived: sum of 2 quarters · filed 2026-08-13 | $1.73M 10-Q · filed 2025-11-13 | $2.98M derived: sum of 4 quarters · filed 2026-08-13 | |||||
| 2025-06-30 | $667.00K 10-Q · filed 2026-08-13 | $1.48M 10-Q · filed 2026-08-13 | $2.73M derived: sum of 3 quarters · filed 2026-08-13 | $2.87M derived: sum of 4 quarters · filed 2026-08-13 | |||||
| 2025-03-31 | $813.00K 10-Q · filed 2026-05-19 | $2.06M derived: sum of 2 quarters · filed 2026-05-19 | $2.20M derived: sum of 3 quarters · filed 2026-05-19 | $5.52M derived: sum of 4 quarters · filed 2026-05-19 | |||||
| 2024-12-31 | $1.25M derived: 10-K 12 month − 10-Q 9 month · filed 2026-03-30 | $1.39M derived: sum of 2 quarters · filed 2026-03-30 | $4.70M derived: sum of 3 quarters · filed 2026-03-30 | $6.98M 10-K · filed 2026-03-30 | |||||
| 2024-09-30 | $143.00K 10-Q · filed 2025-11-13 | $3.46M derived: sum of 2 quarters · filed 2025-11-13 | $5.74M 10-Q · filed 2025-11-13 | $8.24M derived: sum of 4 quarters · filed 2025-11-13 | |||||
| 2024-06-30 | $3.31M 10-Q · filed 2025-08-13 | $5.59M 10-Q · filed 2025-08-13 | $8.10M derived: sum of 3 quarters · filed 2025-08-13 | $7.79M derived: sum of 4 quarters · filed 2025-08-13 | |||||
| 2024-03-31 | $2.28M 10-Q · filed 2025-05-14 | $4.79M derived: sum of 2 quarters · filed 2025-05-14 | $4.47M derived: sum of 3 quarters · filed 2025-05-14 | $4.85M derived: sum of 4 quarters · filed 2025-05-14 | |||||
| 2023-12-31 | $2.51M derived: 10-K 12 month − 10-Q 9 month · filed 2025-04-15 | $2.19M derived: sum of 2 quarters · filed 2025-04-15 | $2.57M derived: sum of 3 quarters · filed 2025-04-15 | $5.45M 10-K · filed 2025-04-15 | |||||
| 2023-09-30 | -$314.00K 10-Q · filed 2024-11-19 | $57.15K derived: sum of 2 quarters · filed 2024-11-19 | $2.94M 10-Q · filed 2024-11-19 | ||||||
| 2023-06-30 | $371.15K 8-K · filed 2024-09-06 | $1.52M 10-Q · filed 2024-08-19 | $1.08M 8-K · filed 2024-09-06 | $3.26M 6-K · filed 2023-09-29 | |||||
| 2023-03-31 | $1.73M 10-Q · filed 2024-05-15 | ||||||||
| 2022-12-31 | $3.92M 8-K · filed 2024-09-06 | $9.56M 20-F · filed 2023-05-01 | |||||||
| 2022-06-30 | $2.85M 6-K · filed 2022-09-27 | $4.99M 6-K · filed 2023-09-29 | |||||||
| 2021-12-31 | $9.13M 20-F · filed 2023-05-01 | ||||||||
| 2021-06-30 | $2.18M 6-K · filed 2022-09-27 | $5.71M 6-K · filed 2022-09-27 | |||||||
| 2020-12-31 | $8.82M 20-F · filed 2023-05-01 | ||||||||
| 2020-06-30 | $3.02M 6-K · filed 2021-09-22 | $5.75M 6-K · filed 2021-09-22 | |||||||
| 2019-12-31 | $8.74M 20-F · filed 2022-05-16 | ||||||||
| 2019-06-30 | $3.59M 6-K · filed 2020-09-01 | $1.27M 6-K · filed 2020-09-01 | |||||||
| 2018-12-31 | $11.80M 20-F · filed 2021-04-21 | ||||||||
| 2018-06-30 | $5.12M 6-K · filed 2019-08-29 | $6.13M 6-K · filed 2019-08-29 | |||||||
| 2017-12-31 | $23.29M 20-F · filed 2020-03-31 | ||||||||
| 2017-06-30 | $3.78M 6-K · filed 2018-09-27 | $9.78M 6-K · filed 2018-09-27 | |||||||
| 2016-12-31 | $17.31M 20-F · filed 2019-04-23 | ||||||||
| 2016-06-30 | $5.44M 6-K · filed 2017-08-10 | $6.94M 6-K · filed 2017-08-10 | $8.87M derived: sum of 3 quarters · filed 2018-07-18 | $10.19M derived: sum of 4 quarters · filed 2018-07-18 | |||||
| 2016-03-31 | $1.50M 10-Q · filed 2016-05-12 | $3.43M derived: sum of 2 quarters · filed 2018-07-18 | $4.74M derived: sum of 3 quarters · filed 2018-07-18 | $5.74M derived: sum of 4 quarters · filed 2018-07-18 | |||||
| 2015-12-31 | $1.93M derived: 20-F 12 month − 10-Q 9 month · filed 2018-07-18 | $3.24M derived: sum of 2 quarters · filed 2018-07-18 | $4.24M derived: sum of 3 quarters · filed 2018-07-18 | $5.80M 20-F · filed 2018-07-18 | |||||
| 2015-09-30 | $1.31M 10-Q · filed 2015-11-23 | $2.31M derived: sum of 2 quarters · filed 2017-04-14 | $3.87M 10-Q · filed 2015-11-23 | $4.95M derived: sum of 4 quarters · filed 2017-04-14 | |||||
| 2015-06-30 | $1.00M 6-K · filed 2017-04-14 | $142.00K 10-Q · filed 2015-08-12 | $2.56M 6-K · filed 2017-04-14 | $1.69M 10-Q · filed 2015-08-12 | $3.63M derived: sum of 3 quarters · filed 2017-04-14 | $3.79M derived: sum of 4 quarters · filed 2017-04-14 | |||
| 2015-03-31 | $1.55M 10-Q · filed 2016-05-12 | $1.55M 10-Q · filed 2015-05-12 | $2.63M derived: sum of 2 quarters · filed 2017-03-31 | $2.79M derived: sum of 3 quarters · filed 2017-03-31 | $4.33M derived: sum of 4 quarters · filed 2017-03-31 | ||||
| 2014-12-31 | $1.08M derived: 20-F 12 month − 10-Q 9 month · filed 2017-03-31 | $1.24M derived: sum of 2 quarters · filed 2017-03-31 | $2.78M derived: sum of 3 quarters · filed 2017-03-31 | $1.62M 20-F · filed 2017-03-31 | $6.42M 10-K · filed 2015-02-11 | ||||
| 2014-09-30 | $162.57K 10-Q · filed 2015-11-23 | $1.70M derived: sum of 2 quarters · filed 2015-11-23 | $539.97K 10-Q · filed 2015-11-23 | ||||||
| 2014-06-30 | $1.54M 10-Q · filed 2015-08-12 | $2.34M 10-Q · filed 2015-08-12 | |||||||
| 2014-03-31 | $800.00K 10-Q · filed 2015-05-12 | ||||||||
| 2013-12-31 | $1.28M 10-K · filed 2015-02-11 | $7.12M 20-F · filed 2014-03-24 | |||||||
| 2012-12-31 | $1.48M 10-K · filed 2015-02-11 | $5.84M 20-F/A · filed 2013-04-19 | |||||||
| 2011-12-31 | $841.00K 20-F · filed 2014-03-24 | ||||||||
| 2010-12-31 | $247.00K 20-F/A · filed 2013-04-19 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| ELI LILLY & Co (LLY) | United States | $1,113.804B | 42.28 |
| JOHNSON & JOHNSON (JNJ) | United States | $652.528B | 29.10 |
| AbbVie Inc. (ABBV) | United States | $468.180B | 70.37 |
| Merck & Co., Inc. (MRK) | United States | $365.215B | 99.96 |
| ABBOTT LABORATORIES (ABT) | United States | $176.045B | 28.47 |
| PFIZER INC (PFE) | United States | $162.042B | 31.94 |
| VERTEX PHARMACEUTICALS INC / MA (VRTX) | United States | $132.481B | 28.56 |
| BRISTOL MYERS SQUIBB CO (BMY) | United States | $125.637B | 12.67 |
| REGENERON PHARMACEUTICALS, INC. (REGN) | United States | $74.751B | 21.53 |
| ALNYLAM PHARMACEUTICALS, INC. (ALNY) | United States | $33.420B | 54.94 |